Early detection remains one of the most critical factors in improving breast cancer outcomes. While mammography continues to be the foundation of breast screening programmes, it has well-documented limitations for women with dense breast tissue. Over 40 percent of women fall into this category, and in dense breasts, cancer can be difficult to identify on mammograms alone because both dense tissue and tumours appear white on the image. This masking effect can delay diagnosis and reduce clinical confidence.

Invenia™ ABUS 2.0 has been developed specifically to address this challenge. As an advanced automated breast ultrasound solution, it provides supplemental imaging that supports the earlier detection of breast cancer in women with dense breast tissue. Clinical studies have demonstrated that when ABUS is used alongside mammography, additional cancers can be identified that would otherwise remain undetected. Importantly, many of these cancers are small, invasive and node-negative, meaning they are found at a stage where treatment options are broader and outcomes are more favourable.

Now available in Ireland from MDI Medical, Invenia ABUS 2.0 combines high-quality 3D ultrasound imaging with intelligent software designed to support radiologists in their daily practice. The system uses an operator-independent acquisition method to ensure consistent, reproducible exams, reducing variability and supporting standardised imaging across departments. The unique coronal view provides a global perspective of the breast, allowing radiologists to visualise architectural distortions and multifocal disease more clearly than with traditional handheld ultrasound alone.

The addition of AI-assisted tools further enhances diagnostic confidence by supporting lesion characterisation and streamlining image review. This can help reduce unnecessary benign biopsies while also supporting radiologists as case volumes and workload continue to grow. For healthcare providers, this means improved efficiency without compromising diagnostic quality.

Patient experience has also been a key consideration in the design of Invenia ABUS 2.0. The gently contoured transducer follows the natural shape of the breast, helping to ensure comfort and full tissue contact during the exam. The scan is non-invasive, does not involve radiation and can be completed efficiently, contributing to high patient acceptance and reassurance. Studies have shown exceptionally positive patient feedback, with women reporting a willingness to recommend ABUS screening to others.

Beyond screening, Invenia ABUS 2.0 supports the entire breast care pathway. The reproducible 3D datasets assist in diagnostic assessment, treatment planning and staging, while also enabling reliable monitoring of treatment response, including during neoadjuvant chemotherapy. By helping to detect cancer earlier and support more precise clinical decisions, ABUS can contribute to improved patient outcomes and, potentially, reduced downstream healthcare costs.

MDI Medical provides comprehensive support for Invenia ABUS 2.0 in Ireland, ensuring healthcare providers can implement the technology with confidence. This includes system installation, on-site clinical and technologist training, education programmes and ongoing technical support. With a strong focus on partnership and service, MDI Medical helps imaging teams integrate ABUS smoothly into existing workflows.

As breast imaging continues to evolve towards more personalised screening strategies, Invenia ABUS 2.0 offers a powerful solution for addressing the challenges of dense breast tissue. By combining advanced 3D ultrasound imaging, AI-enabled assistance and a strong support framework, it enables clinicians to deliver more proactive, confident and patient-centred breast care.